Rocket Pharmaceuticals (NASDAQ:RCKT) Posts Earnings Results, Beats Expectations By $0.04 EPS

robot
Abstract generation in progress

Rocket Pharmaceuticals (NASDAQ:RCKT) announced its quarterly earnings, reporting an EPS of ($0.38), which beat the consensus estimate by $0.04. The stock saw a trading increase to $4.53, with a market capitalization of $490 million, despite some insider selling by the CEO and General Counsel. Analysts currently hold a consensus “Hold” rating for RCKT with an average price target of $14.36.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin

Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate App
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский язык
  • Français
  • Deutsch
  • Português (Portugal)
  • ภาษาไทย
  • Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)